Pacer Advisors
MRVI icon

Pacer Advisors’s Maravai LifeSciences MRVI Stock Holding History

Pacer Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,955,230
Closed -$19.4M – 3704
2023
Q4 		$19.4M Buy
2,955,230
+810,957
+38% +$5.24M 0.05% 302
2023
Q3 		$21.4M Buy
2,144,273
+69,479
+3% +$763K 0.08% 231
2023
Q2 		$25.8M Buy
2,074,794
+34,601
+2% +$467K 0.1% 203
2023
Q1 		$28.6M Buy
2,040,193
+388,292
+24% +$5.58M 0.12% 172
2022
Q4 		$23.6M Buy
1,651,901
+991,860
+150% +$15.6M 0.12% 142
2022
Q3 		$16.9M Buy
+660,041
New +$16.6M 0.12% 139

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pacer Advisors's MRVI Position: Q1 2024 in Review

Pacer Advisors sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 2,955,230 shares — an estimated $19.4M sold.

Pacer Advisors first reported a position in MRVI in Q3 2022 and held it in 6 quarters. The position peaked at $28.6M in Q1 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Pacer Advisors reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Pacer Advisors sold 2,955,230 Maravai LifeSciences shares in Q1 2024, an estimated $19.4M.
  • Pacer Advisors first reported a position in Maravai LifeSciences in Q3 2022 and held it in 6 quarters.
  • Pacer Advisors's Maravai LifeSciences position peaked at $28.6M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Pacer Advisors's 13F filing for Q1 2024, filed 10 May 2024.